What were Kwality Pharmaceuticals Ltd's latest quarterly results?
Kwality Pharmaceuticals Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +78.6% (accelerating)
- Revenue Growth YoY: +35.3%
- Operating Margin: 25.0% (expanding)
Kwality Pharmaceuticals Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +59.2%Strong11w Streak
In , Kwality Pharmaceuticals Ltd (Pharma - Formulators) is outperforming Nifty 500 with +59.2% relative strength. Fundamentals: Strong. On a 11-week streak.
Kwality Pharmaceuticals Ltd Key Facts
- PE Ratio
- 37.2x
- Market Cap
- ₹2,531 Cr
- PAT Growth YoY
- +79%
- Revenue Growth YoY
- +35%
- OPM
- 25.0%
- RS vs Nifty 500
- +59.2%
PE: At PeakFull Momentum
What's Happening
🚀Both earnings and PE expanding — full momentum mode
🎯Earnings accelerating with expanding margins — double tailwind
💪Debt reduced 15% YoY — balance sheet strengthening
💰Trading 4% above estimated fair value
Key Numbers
PAT Growth YoY
+79%
Accelerating
Revenue YoY
+35%
Stable
Operating Margin
25.0%
+300 bps YoY
PE Ratio
37.2
Current Price
₹2,439
Fundamental Score
63/100
Strong
3Y PAT CAGR
+52%
Market Cap
2.5K Cr
Valuation
Fairly Valued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Kwality Pharmaceuticals Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +35% | +26% | Stable |
| PAT (Net Profit) | +79% | +52% | Accelerating |
| OPM | 25.0% | +300 bps | Expanding |
Other Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Kwality Pharmaceuticals Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Kwality Pharmaceuticals Ltd's profit growing or declining?
Kwality Pharmaceuticals Ltd's profit is growing with an accelerating trend.
- PAT Growth YoY: +78.6% (latest quarter)
- PAT Growth QoQ: +56.3% (sequential)
- 3-Year PAT CAGR: +52.2%
- Trend: Accelerating — latest quarter growth stronger than prior
What is Kwality Pharmaceuticals Ltd's revenue growth trend?
Kwality Pharmaceuticals Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +35.3%
- Revenue Growth QoQ: +27.6% (sequential)
- 3-Year Revenue CAGR: +26.1%
How is Kwality Pharmaceuticals Ltd's operating margin trending?
Kwality Pharmaceuticals Ltd's operating margin is expanding.
- Current OPM: 25.0%
- OPM Change YoY: +3.0% basis points
- OPM Change QoQ: +1.0% basis points
What is Kwality Pharmaceuticals Ltd's 3-year profit and revenue CAGR?
Kwality Pharmaceuticals Ltd's long-term compounding rates
- 3-Year Profit CAGR: +52.2%
- 3-Year Revenue CAGR: +26.1%
Is Kwality Pharmaceuticals Ltd's growth accelerating or decelerating?
Kwality Pharmaceuticals Ltd's earnings growth is accelerating with positive momentum on a sequential basis.
- YoY Acceleration: +0.8% bps
- Sequential Acceleration: +35.7% bps
What is Kwality Pharmaceuticals Ltd's trailing twelve month (TTM) performance?
Kwality Pharmaceuticals Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹67 Cr
- TTM PAT Growth: +71.8% YoY
- TTM Revenue: ₹502 Cr
- TTM Revenue Growth: +35.7% YoY
- TTM Operating Margin: 23.6%
Is Kwality Pharmaceuticals Ltd overvalued or undervalued?
Kwality Pharmaceuticals Ltd appears fairly valued based on our fair value analysis.
- Valuation Signal: Fairly Valued
- Current PE: 37.2x
- Price-to-Book: 7.6x
What is Kwality Pharmaceuticals Ltd's current PE ratio?
Kwality Pharmaceuticals Ltd's current PE ratio is 37.2x.
- Current PE: 37.2x
- Market Cap: 2.5K Cr
How does Kwality Pharmaceuticals Ltd's valuation compare to its history?
Kwality Pharmaceuticals Ltd's current PE is 37.2x.
- Current PE: 37.2x
- Valuation Assessment: Fairly Valued
What is Kwality Pharmaceuticals Ltd's price-to-book ratio?
Kwality Pharmaceuticals Ltd's price-to-book ratio is 7.6x.
- Price-to-Book (P/B): 7.6x
- Book Value per Share: ₹320
- Current Price: ₹2439
Is Kwality Pharmaceuticals Ltd a fundamentally strong company?
Kwality Pharmaceuticals Ltd is rated Strong with a fundamental score of 63/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +35.3% (10% weight)
- PAT Growth YoY: +78.6% (10% weight)
- PAT Growth QoQ: +56.3% (10% weight)
- Earnings accelerating (5% weight)
- Margins expanding (10% weight)
Is Kwality Pharmaceuticals Ltd debt free?
Kwality Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹130 Cr
What is Kwality Pharmaceuticals Ltd's return on equity (ROE) and ROCE?
Kwality Pharmaceuticals Ltd's return ratios over recent years
- FY2024: ROCE 16.0%
- FY2025: ROCE 18.0%
- FY2026: ROCE 24.0%
Is Kwality Pharmaceuticals Ltd's cash flow positive?
Kwality Pharmaceuticals Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹17 Cr
- Free Cash Flow (FCF): ₹-18 Cr
- CFO/PAT Ratio: 25% (weak cash conversion)
What is Kwality Pharmaceuticals Ltd's dividend yield?
Kwality Pharmaceuticals Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹2439
Who holds Kwality Pharmaceuticals Ltd shares — promoters, FII, DII?
Kwality Pharmaceuticals Ltd's shareholding pattern (Mar 2026)
- Promoters: 54.9%
- FII (Foreign): 2.8%
- DII (Domestic): 0.4%
- Public: 42.0%
Is promoter holding increasing or decreasing in Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd's promoter holding has increased recently.
- Current Promoter Holding: 54.9% (Mar 2026)
- Previous Quarter: 54.8% (Dec 2025)
- Change: +0.05% (increasing — positive signal)
How long has Kwality Pharmaceuticals Ltd been outperforming Nifty 500?
Kwality Pharmaceuticals Ltd has been outperforming Nifty 500 for 11 consecutive weeks, indicating consistent outperformance.
Is Kwality Pharmaceuticals Ltd a new momentum entry or an established outperformer?
Kwality Pharmaceuticals Ltd is an established outperformer with 11 weeks of consecutive Nifty 500 outperformance.
Is Kwality Pharmaceuticals Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Kwality Pharmaceuticals Ltd may be worth studying
- Earnings growth is accelerating — PAT YoY +78.6%
- Operating margins are expanding — OPM at 25.0%
- Cash flow is positive — CFO ₹17 Cr
What is the investment thesis for Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd investment thesis summary:
Research Signals (Bull Case)
- Earnings accelerating — strongest growth trend
- Revenue growing at +35.3% YoY
- Margins expanding
What is the future outlook for Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd's forward outlook based on current data signals
- Earnings Trend: accelerating
- Revenue Trend: stable
- Margin Trend: expanding
- Valuation: Fairly Valued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.